Compagnie Lombard Odier SCmA Reduces Holdings in AbbVie Inc. $ABBV

Compagnie Lombard Odier SCmA reduced its stake in AbbVie Inc. (NYSE:ABBV) by 1.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 306,202 shares of the company’s stock after selling 3,902 shares during the period. AbbVie comprises 0.8% of Compagnie Lombard Odier SCmA’s investment portfolio, making the stock its 28th largest position. Compagnie Lombard Odier SCmA’s holdings in AbbVie were worth $70,898,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie during the second quarter worth about $26,000. Spurstone Advisory Services LLC bought a new position in AbbVie during the 2nd quarter valued at approximately $28,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie in the 2nd quarter worth approximately $36,000. Delos Wealth Advisors LLC purchased a new stake in AbbVie in the 2nd quarter worth approximately $39,000. Finally, Access Investment Management LLC bought a new stake in shares of AbbVie in the 2nd quarter worth approximately $44,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Raymond James Financial set a $256.00 target price on AbbVie in a report on Monday, November 3rd. Citigroup decreased their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday, January 27th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 target price on shares of AbbVie in a research note on Wednesday, January 28th. Guggenheim increased their price target on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Finally, HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $251.00.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $223.00 on Tuesday. The company has a 50 day simple moving average of $223.71 and a two-hundred day simple moving average of $220.07. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a market capitalization of $394.13 billion, a price-to-earnings ratio of 94.49, a P/E/G ratio of 0.85 and a beta of 0.35.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the business posted $2.16 EPS. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.